Based on the magnitude of the DDI and the target population of patients with AML, who routinely require use of anti-fungal agents (such as azoles, which are CYP3A4 inhibitors), the clinical dose of glasdegib was selected as 100-mg QD for further clinical evaluation. The gene discussed is CYP3A4; the disease is acute myeloid leukemia.